Title
Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.

Permalink
https://escholarship.org/uc/item/4235n3z6

Journal
Journal of thrombosis and thrombolysis, 46(4)

ISSN
0929-5305

Authors
Jackson, Larry R
Kim, Sunghee
Shrader, Peter
et al.

Publication Date
2018-11-01

DOI
10.1007/s11239-018-1715-1

Peer reviewed
Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry

Larry R. Jackson II · Sunghee Kim · Peter Shrader · Rosalia Blanco · Laine Thomas · Michael D. Ezekowitz · Jack Ansell · Gregg C. Fonarow · Bernard J. Gersh · Alan S. Go · Peter R. Kowey · Kenneth W. Mahaffey · Elaine M. Hylek · Eric D. Peterson · Jonathan P. Piccini Sr.

Published online: 26 July 2018
© The Author(s) 2018

Abstract
Anticoagulation is highly effective for the prevention of stroke in patients with atrial fibrillation (AF) but it is dependent on patients continuing therapy. While studies have demonstrated suboptimal therapeutic persistence on warfarin, few have studied persistence rates with non vitamin K antagonist oral anticoagulants (NOACs) such as dabigatran. We examined rates of continued use of dabigatran versus warfarin over 1 year among AF patients in the ORBIT-AF registry between June 29, 2010 and August 09, 2011. Multivariable logistic regression analysis was used to identify characteristics associated with 1-year persistent use of dabigatran therapy or warfarin. At baseline, 6.4 and 93.6% of 7150 AF patients were on dabigatran and warfarin, respectively. At 12 months, dabigatran-treated patients were less likely to have continued their therapy than warfarin-treated patients [Adjusted persistence rates: 66% (95% CI 60–72) vs. 82% (95% CI 80–84), \( p < .0001 \)]. Predictors of dabigatran persistence included: CHA2DS2-VASc risk scores ≥ 2 OR 5.69, (95% CI 1.50–21.6) and BMI greater than 25 mg/m² but less than 38 kg/m² 1.05 (1.01–1.09). Predictors of persistence on warfarin included: African American race (vs. White) 1.53 (1.07–2.19), Hispanic ethnicity (vs. White) 1.66 (1.06–2.60), paroxysmal and persistent AF (vs. new-onset) 1.68 (1.21–2.33) and 1.91 (1.35–2.69) respectively, LVH 1.40 (1.08–1.81), and CHA2DS2-VASc risk scores ≥ 2 1.94 (1.18–3.19). While 1-year persistence rates for dabigatran were lower than warfarin, persistence rates for both agents were not ideal. Future studies evaluating contemporary persistence are needed in order to assist in better targeting interventions aimed to improve anticoagulation persistence.

Keywords Atrial fibrillation · Oral anticoagulation · Dabigatran · Warfarin

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s11239-018-1715-1) contains supplementary material, which is available to authorized users.

Larry R. Jackson II
larry.jackson@dm.duke.edu

1 Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
2 Hofstra North Shore/LIJ School of Medicine, Hempstead, New York, USA
3 UCLA Division of Cardiology, Los Angeles, CA, USA
4 Mayo Clinic College of Medicine, Rochester, MN, USA
5 Kaiser Permanente, Oakland, CA, USA
6 Lankenau Institute for Medical Research, Jefferson Medical College, Wynnewood, PA, USA
7 Division of Cardiovascular Medicine, Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, CA, USA
8 Boston University School of Medicine, Boston, MA, USA
9 Division of Cardiovascular Medicine, Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Suite 7009, Durham, NC 27705, USA
Highlights

- There is a paucity of real-world data on the persistence of drug therapy between warfarin and non vitamin K antagonist oral anticoagulants.
- ORBIT-AF was used to compare the persistence of warfarin vs. dabigatran in a contemporary cohort of AF patients.
- Warfarin persistence was greater than dabigatran at 6 and 12 months, respectively.
- Future studies evaluating persistence of other non vitamin K antagonist oral anticoagulants as well as the implementation of effective strategies to improve persistence are needed.

Introduction

Guideline recommended management of patients with AF includes long-term anticoagulant prophylaxis to prevent ischemic stroke in patients with more than 1 risk factor for stroke [1]. Traditional vitamin K antagonist (VKA) oral anticoagulants such as warfarin were previously the gold standard for stroke prevention but require dose adjustments, frequent coagulation laboratory monitoring, vigilance over numerous potential drug–drug interactions, and increased risk of bleeding; all factors that can potentially lead to drug discontinuation. Direct oral anticoagulants such as dabigatran are currently being used for the prevention of stroke and systemic embolism in patients with non-valvular AF [2]. However, it is unclear whether persistence with dabigatran exceeds that of warfarin.

Accordingly, we used the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) to perform the following: (1) compare the persistence of dabigatran early after the introduction in clinical practice versus warfarin therapy (2) examine predictors associated with the persistence of each drug; and (3) describe the stated indications for discontinuation of each drug.

Methods

Study population

We used the ORBIT-AF registry to assess persistence rates for dabigatran and warfarin over 1-year of follow-up. Between June 29, 2010 and August 09, 2011, 7150 patients treated with warfarin [N = 6691 (93.6%)] and dabigatran [N = 459 (6.4%)] at baseline were enrolled in the ORBIT-AF registry. The rationale and design of the ORBIT-AF registry have been previously described [3].

Data collection and study endpoints

Persistence with dabigatran and warfarin were defined as continuous use between baseline, 6 months, and 1-year follow-up. If a patient discontinued taking dabigatran or warfarin at 6 months or 1 year, for any reason, he or she was defined as discontinuing dabigatran or warfarin and therefore, not persistent. For those patients who discontinued either dabigatran or warfarin at their 6 months and/or 1-year follow-up, providers were asked to identify one or more primary and secondary reasons for discontinuation from a pre-specified list [4].

Statistical analysis

We compared baseline characteristics between patients treated with dabigatran and patients treated with warfarin over 1 year of follow-up. The differences across two groups were assessed using Wilcoxon rank-sum test for continuous variables and the chi square test for categorical variables. The data are presented as medians (interquartile range) for continuous variables and as percentages for categorical variables. In order to assess the difference of persistence rates between warfarin and dabigatran at 6 months or 1 year, a p value will be presented using chi square test. Adjusted persistence rates were calculated using inverse probability weighting [IPW] analysis incorporating propensity scores to minimize difference between people taking dabigatran and warfarin. The propensity score was obtained from a logistic regression model for dabigatran use [4]. Persistence rates for both warfarin and dabigatran were then re-calculated using inverse propensity weighting to balance the characteristics of patients receiving these two treatments. In addition, 6 and 12 month adjusted persistence rates were calculated among specific subgroups including: age > 75, women, creatinine clearance < 50 ml/min/1.73 m², and concomitant antiplatelet therapy. Multi-variable logistic regression was used to determine factors associated with persistence of dabigatran and warfarin. Local institutional review boards approved this study.

Results

Patient characteristics

Patients treated with dabigatran were younger (median 71 vs. 74 years, p < .0001), had higher left ventricular ejection fractions, higher creatinine clearance (88 vs. 77 ml/min/1.73 m², p < .0001), lower CHA2DS2-VASc risk scores, and fewer
prior stroke or transient ischemic attacks events (11 vs. 16%, $p = .003$) than those treated with warfarin. Patients treated with dabigatran had more severe symptoms (EHRA class III: 20 vs. 14%, $p < .0001$), higher rates of management with a rhythm control strategy (43 vs. 28%, $p < .0001$), more attempts at cardioversion (38 vs. 32%, $p < .006$), and more frequent catheter ablation of AF (10 vs. 5%, $p < .0001$) than those treated with warfarin.

**Persistence of therapy**

Adjusted 6 and 12 month persistence rates were as follows: 6 months, dabigatran versus warfarin: 78% (95% CI 72–84) versus 89% (95% CI 87–90), $p < .0001$; 12 months, dabigatran versus warfarin: 66% (95% CI 60–72) versus 82% (95% CI 80–84), $p < .0001$ (Fig. 1). The number of patients who discontinued warfarin and dabigatran at 6 and 12 months is as follows: (6 months: warfarin [675 (10.5%)], dabigatran [104 (23.8%)]; 12 months: warfarin [1159 (17.3%)], dabigatran [169 (36.8%)]). We analyzed persistence of therapy in several special patient groups including: age > 75, females, estimated creatinine clearance (CrCl) less than 50 ml/min/1.73 m$^2$ (Cockcroft-Gault), and patients receiving concomitant antiplatelet therapy (ASA or P2Y$_{12}$ receptor inhibitor). All groups demonstrated lower adjusted 6 month and 1 year persistence for dabigatran versus warfarin (Supplemental Material).

### Table 1 Predictors of dabigatran and warfarin persistence

| Risk factor                              | Dabigatran adjusted HR (95% CI) | $p$ value | Warfarin adjusted HR (95% CI) | $p$ value |
|------------------------------------------|---------------------------------|-----------|-------------------------------|-----------|
| Duration of AF < 3 years                 | –                               | –         | 1.15 (1.10–1.22)              | < .0001   |
| Prior catheter ablation of AF            | –                               | –         | 0.58 (0.45–0.74)              | < .0001   |
| Most recent ECG-sinus rhythm             | –                               | –         | 0.72 (0.61–0.85)              | < .0001   |
| Age, years (per 10 year increase)        | –                               | –         | 1.14 (1.06–1.22)              | .0002     |
| Persistent AF vs. first onset            | –                               | –         | 1.91 (1.35–2.69)              | .0002     |
| Cognitive impairment                     | –                               | –         | 0.56 (0.40–0.80)              | .001      |
| Paroxysmal AF vs. first onset            | –                               | –         | 1.68 (1.21–2.33)              | .002      |
| Heart rate > 80                          | –                               | –         | 0.94 (0.90–0.98)              | .004      |
| CHA$_2$DS$_2$VASC high vs. low           | 5.69 (1.50–21.55)               | .01       | 1.94 (1.18–3.19)              | .009      |
| 25 < BMI ≤ 38                            | 1.05 (1.01–1.09)                | .02       | –                             | –         |
| LVH                                      | –                               | –         | 1.40 (1.08–1.81)              | .01       |
| Permanent AF vs. first onset             | –                               | –         | 1.55 (1.08–2.23)              | .02       |
| African American vs. White               | –                               | –         | 1.53 (1.07–2.19)              | .02       |
| Hispanic vs. White                       | –                               | –         | 1.66 (1.06–2.60)              | .03       |
| CHA$_2$DS$_2$VASC medium vs. low         | 3.95 (0.95–16.38)               | .06       | 1.12 (0.66–1.92)              | .67       |
Characteristics and predictors of warfarin and dabigatran persistence

Predictors of persistence of warfarin included: age, duration of AF < 3 years, African American race and Hispanic ethnicity, LVH, and more permanent forms of AF such as persistent and permanent AF. Predictors of persistent use of dabigatran included: medium and high CHA₂DS₂-VASc scores, defined as a score of 1 and ≥ 2 respectively, and BMI greater than 25 but less than or equal to 38 kg/m² (Table 1).

Indications for discontinuation

The most commonly reported reasons for dabigatran discontinuation were physician preference, other indications, and patient refusal followed by bleeding events, GI upset, and high bleeding risk (Fig. 1). Similarly, the two most common reasons for warfarin discontinuation were physician preference and patient refusal.

Discussion

Quality care to reduce the risk of stroke in patients with AF requires both the initiation of stroke prevention and persistent therapy over the long-term. Our analysis yields several important findings. First and foremost, 1-year persistence rates for patients who received warfarin were higher than those receiving dabigatran. Patients who persisted on warfarin were older, and more likely to be an underrepresented minority, increased number of co-morbid medical illness, and to have more permanent forms of AF compared to patients who persisted on dabigatran. Finally, the most frequent reasons for discontinuation for both warfarin and dabigatran are physician preference, patient refusal, and bleeding.

For decades, warfarin has been the standard of care oral anticoagulant with respect to the prevention of stroke and systemic embolism for patients with AF [5, 6]. While dabigatran is an attractive alternative to warfarin with significant benefits, it is not clear which agent has better persistence with therapy over time. In the RE-LY trial, Connolly et al. showed that 2-year persistence rates were higher for warfarin compared with dabigatran (83 vs. 79%) [2]. Alternatively, in a retrospective cohort using administrative claims data, Zalesak et al., reported that patients who initiated dabigatran treatment demonstrated higher persistence rates than those receiving warfarin therapy at both 6 months (72 vs. 53%) and 1-year (63 vs. 39%) [7].

Our results are from a prospective, contemporary cohort of AF patients. We report a higher rate of warfarin persistence compared to dabigatran, and significantly higher rates of warfarin persistence than prior studies [8–10]. The higher rates of persistence in this study may reflect contemporary trends of enhanced utilization of resources used to monitor and manage warfarin therapy or participation by patients in a registry focused on oral anticoagulation and quality of care. Of note, in the multivariable models for persistence, prior warfarin therapy was not a significant predictor of continued warfarin or dabigatran persistence at 1-year. In addition, warfarin persistence may have been higher due to a longer history of prevalent warfarin use compared to dabigatran, which would promote greater familiarity with warfarin therapy. The lower persistence rates of dabigatran cannot be entirely attributed to actual drug therapy but circumstances between patients taking dabigatran versus warfarin including drug switching or NOAC initiation and not therapeutic failure of drug therapy with dabigatran.

Despite the fact that persistence was higher with warfarin, our data also show that current persistence rates with dabigatran may be higher than those previously reported. For example, an analysis of pharmacy claims data from October 29, 2010 through June 30, 2011 by Tsai et al. found that dabigatran persistence was approximately 60% at 6 months [11] compared with 79% in ORBIT AF. Similar to the GLORIA investigators, our study documents high levels of dabigatran persistence [12].

Physician preference was the primary indication for discontinuation of both warfarin and dabigatran. Previous studies have shown that indications for warfarin discontinuation are primarily guided by physician preference suggesting that long-term persistence with warfarin may be affected by physician concern for safety when prescribing this drug [4, 13]. In addition, our findings confirm work from prior studies showing that bleeding events and gastrointestinal side effects are common reasons for discontinuation of dabigatran [14].

Limitations

Several limitations need to be acknowledged when considering these data. First, as with all observational analyses, we cannot exclude that after adjustment, the possibility of residual measured or unmeasured confounding exist which may have led to an overestimation and underestimation of warfarin and dabigatran persistence, respectively. Second, the ORBIT-AF study population was derived from practices participating in a US registry and may not be representative of all AF patients in general. In addition, the enrollment of patients for this analysis occurred shortly after the approval of dabigatran (October 2010) and may not represent contemporary persistence trends with this specific direct oral anticoagulant. Finally, we did not analyze the impact of non-persistence on clinical outcomes, although prior studies have
demonstrated that persistence with anticoagulation therapy is strongly associated with outcomes [15, 16].

**Conclusion**

In this prospective non-randomized observational comparison of ORBIT registry patients with AF who received dabigatran early after introduction into clinical practice versus warfarin, we found significantly lower persistence with dabigatran treated patients within 6 months and 1-year.

**Funding** The ORBIT-AF and ORBIT-AF II registries are sponsored by Janssen Scientific Affairs, LLC (Raritan, NJ).

**Compliance with ethical standards**

**Conflict of interest** Drs. Larry R. Jackson II reports honoraria from Biotronik Inc. Sung Hee Kim, Peter Shrader, Rosalia Blanco and Laine Thomas have no pertinent relationships related to the analysis presented. Dr. Jonathan P. Piccini Sr. receives research grants from ARCA biopharma, Boston Scientific, GE Healthcare, Johnson & Johnson, and ResMed; he also has received consulting fees from Janssen Pharmaceuticals, and Spectranetics. Dr. Bernard Gersh receives consulting fees from Ortho-McNeil-Janssen Pharmaceuticals. Dr. Ezekowitz receives consulting fees from Janssen Pharmaceuticals. Dr. Ansell receives consulting fees from Janssen Pharmaceuticals. Dr. Hylek reports honoraria for consultancy from Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Medtronic & Pfizer Dr. Gregg C. Fonarow receives consulting fees from Janssen Pharmaceuticals. Dr. Alan S. Go receives consulting fees from Janssen Pharmaceuticals. Dr. Kenneth W. Mahaffey receives research grants from Medtronic and St. Jude; he has also received consulting fees the American College of Cardiology, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Elsevier, Forest, Glaxo-Smith-Kline, Johnson & Johnson, Medtronic, Merck, Portola Pharma, Spring Publishing, and The Medicines Company, WebMD. Dr. Peterson receives research grants from Eli Lilly & Company and Janssen Pharmaceutical Products; he also has received consulting fees from Boehringer Ingelheim, Janssen Pharmaceutical Products, Merck & Co., and Sanofi Aventis. Dr. Peter Kowey receives consulting fees from Johnson and Johnson.

**Informed consent** Informed consent was obtained for all patients participating in the ORBIT-AF as detailed in the “Methods” section.

**Research involving human participants** This article does not contain any studies with human participants performed by any of the authors.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB et al (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130:2071–2104
2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151
3. Piccini JP, Fraulo ES, Ansell JE, Fonarow GC, Gersh BJ, Go AS, Hylek EM et al (2011) Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J 162:606–612
4. O’Brien EC, Simon DN, Allen LA, Singer DE, Fonarow GC, Kowey PR, Thomas LE et al (2014) Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J 168:487–494
5. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B (1989) Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1:175–179
6. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinrauf H et al (1992) Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation: Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 327:1406–1412
7. Zalesak M, Miu K, Francis K, Yu C, Alvrtssyan H, Rao Y, Walker D et al (2013) Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 6:567–574
8. Gallagher AM, Rietbrock S, Plumb J, van Staa TP (2008) Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 6:1500–1506
9. Glader EL, Sjolander M, Eriksson M, Lundberg M (2010) Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke 41:397–401
10. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE (2010) Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes 3:624–631
11. Tsai K, Erickson SC, Yang J, Harada AS, Solow BK, Lew HC (2013) Adherence, persistence, and switching patterns of dabigatran etexilate. Am J Manag Care 19:e325–e332
12. Paquette M, Riou Franca L, Teutsch C, Diener HC, Lu S, Dubner SJ, Ma CS et al (2017) Persistence with dabigatran therapy at 2 years in patients with atrial fibrillation. J Am Coll Cardiol 70:1573–1583
13. Deckert C, Garavalia L, Garavalia B, Simon T, Loeb M, Spretus JA, Daniel WC (2012) Exploring barriers to optimal anticoagulation for atrial fibrillation: interviews with clinicians. J Multidiscip Healthc 5:129–135
14. Michel J, Mundell D, Boga T, Sasse A (2013) Dabigatran for anticoagulation in atrial fibrillation: early clinical experience in a hospital population and comparison to trial data. Heart Lung Circ 22:50–55
15. Shore S, Carey EP, Turakhia MP, Jackevicius CA, Cunningham F, Pilote L, Bradley SM et al (2014) Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Am Heart J 167:810–817
16. Beyer-Westendorf J, Ebertz F, Forster K, Gelbrich V, Michalski F, Kohler C, Werth S et al (2015) Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry. Thromb Haemost 113:1247–1257